Solid Biosciences Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Boston, MA USA
Total Funding:$217.5M
Lead Investor(s):J.P. Morgan, Goldman Sachs & Co. LLC
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Solid Biosciences's estimated annual revenue is currently $12.4M per year.
  • Solid Biosciences received $133.7M in venture funding in February 2018.
  • Solid Biosciences's estimated revenue per employee is $125,253
  • Solid Biosciences's total funding is $217.5M.

Employee Data

  • Solid Biosciences has 99 Employees.
  • Solid Biosciences grew their employee count by -34% last year.
  • Solid Biosciences currently has 1 job openings.

Executive Contacts

Lineka GousbyOffice Manager
Debra SegalVice President, Regulatory Affairs
Kara ClarkeSenior Manager, Talent Acquisition
Angel CortesSr Manager, Quality Control
Patrick RedmanSenior Project Manager, R&D
Kristy BrownAssociate Director R&D
Christine KitsosDirector, Head of Analytical Development
Alvaro AmorrortuChief Operating Officer
Susan RedicanSenior Director, Clinical Operations
Pamela LawrenceExecutive Assistant To Cso And Cto

Solid Biosciences (Solid) is a Cambridge, MA based biotech company singularly focused on developing treatments and cures for Duchenne muscular dystrophy (DMD). Solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of DMD.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ohana Bioscienc...
Tango Therapeut...
Compass Therape...
Hamilton Storag...
Alnylam Pharmac...
Berkshire Corpo...
Repligen Corpor...
Allena Pharmace...

Solid Biosciences News

31-Aug-19 - Citi: Solid Biosciences Rally Unsupported By Fundamentals

Following the near 100% rally in shares of Solid Biosciences Inc (NASDAQ: SLDB) in August, one Citigroup analyst said the stock price is ...

31-Aug-19 - Solid Biosciences Stock Falls as Analyst Says Nothing Fundamental Has Changed

Shares of the gene therapy biotech specialist Solid Biosciences slid Thursday morning as an analyst at Citi Research argued that it was time to ...

31-Aug-19 - Solid Biosciences Inc. (NasdaqGS:SLDB) Quant Signals Under The Gun as EV Hits 375097

Investors are constantly examining different company financial indicators to assess trading opportunities. Solid Biosciences Inc.

Solid Biosciences Funding

DateAmountRoundLead InvestorsReference
2015-11-04$42.5MBerceptive Advisors, LLCArticle
2017-03-31$50.0MCRA Capital ManagementArticle
2018-02-01$133.7MUndisclosedJ.P. MorganArticle